German American Bancorp Inc. lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,508 shares of the medical research company's stock after selling 680 shares during the period. German American Bancorp Inc.'s holdings in Thermo Fisher Scientific were worth $4,946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of TMO. Renaissance Group LLC lifted its position in Thermo Fisher Scientific by 3.4% during the fourth quarter. Renaissance Group LLC now owns 54,944 shares of the medical research company's stock valued at $28,583,000 after acquiring an additional 1,819 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Thermo Fisher Scientific by 270.5% during the 4th quarter. Renaissance Technologies LLC now owns 181,344 shares of the medical research company's stock valued at $94,341,000 after purchasing an additional 132,393 shares during the last quarter. FIL Ltd boosted its position in shares of Thermo Fisher Scientific by 58.5% in the 4th quarter. FIL Ltd now owns 347,139 shares of the medical research company's stock worth $180,592,000 after purchasing an additional 128,095 shares in the last quarter. Canopy Partners LLC grew its stake in Thermo Fisher Scientific by 79.9% during the 4th quarter. Canopy Partners LLC now owns 2,250 shares of the medical research company's stock worth $1,171,000 after buying an additional 999 shares during the last quarter. Finally, Rathbones Group PLC raised its stake in Thermo Fisher Scientific by 6.5% in the fourth quarter. Rathbones Group PLC now owns 796,317 shares of the medical research company's stock valued at $414,268,000 after buying an additional 48,825 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Thermo Fisher Scientific
In other news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by company insiders.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the stock. Barclays cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday. StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a research report on Friday, January 31st. Finally, Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target on the stock in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average target price of $647.43.
Check Out Our Latest Analysis on TMO
Thermo Fisher Scientific Stock Performance
Shares of TMO traded up $10.47 during trading hours on Friday, hitting $437.91. The stock had a trading volume of 2,656,544 shares, compared to its average volume of 1,698,824. The firm has a market capitalization of $165.21 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a 50-day moving average price of $510.56 and a 200 day moving average price of $538.78. Thermo Fisher Scientific Inc. has a fifty-two week low of $409.85 and a fifty-two week high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.41%.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
